KR-20260065824-A - Surfactants for use in healthcare products

KR20260065824AKR 20260065824 AKR20260065824 AKR 20260065824AKR-20260065824-A

Abstract

A healthcare formulation comprising the surfactant or active ingredient of the present invention, formulated as a solid, liquid, or emulsion. The present disclosure provides healthcare products, e.g., prescription drugs, over-the-counter drugs; mineral, herbal, and/or vitamin supplements; drugs administered in hospitals, clinics, doctors' offices, and palliative care locations; formulations of vaccines, tissues, organs, and cell transplants and/or grafts and/or infusions; and wound care formulations comprising topical ointments, lotions, cleansers, wipes, bandages, and dressings. The active ingredient may be included in the formulation as a solute, solvent, particle, or oil-immiscible component of the formulation. The active ingredient may be included in tablets, capsules, tinctures, liquids, or emulsions. The healthcare formulations of the present invention include formulations suitable for oral, topical, and/or injection administration.

Inventors

아시르바탐, 에드워드
아난타파드마나반, 카브세리
쿠마리, 하르시타
미타팔리, 라마나
파니그라히, 수치트라

Assignees

어드밴식스 레진즈 앤드 케미컬즈 엘엘씨

Dates

Publication Date: 20260511
Application Date: 20240807
Priority Date: 20240805

Claims (15)

Solid healthcare preparations including the following: At least one surfactant of chemical formula I: Herein, R1 and R2 are the same or different and comprise at least one group selected from the group consisting of C1 - C6 alkyls, optionally the C1 - C6 alkyl may comprise one or more of oxygen, nitrogen, or sulfur atoms or a group comprising at least one of these atoms, and the alkyl chain may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate; R3 is selected from the group consisting of alkenyl, alkynyl, ester, alcohol, aryl alkyl, alkoxyalkyl ether, alkyl phosphate, C3 - C8 carboxylic acid, C1 - C10 alkyl benzoic acid, and a C1 - C6 linker attached to a second molecule of formula I, wherein the second molecule is the same or different; n is an integer from 1 to 12; X is selected from the group consisting of chlorides, bromides, and iodides; and At least one active ingredient.
A preparation according to claim 1, wherein at least one active agent is selected from the group consisting of drugs, proteins, cells, tissues, vitamins, supplements, and minerals.
A formulation according to claim 1 or 2, further comprising one or more excipients selected from the group consisting of binders, fillers, disintegrants, salts, coloring agents, sweeteners, and flavoring agents.
A formulation comprising a powder, tablet, or capsule in any one of paragraphs 1 to 3.
Liquid formulations for healthcare comprising the following: At least one surfactant of chemical formula I: Herein, R1 and R2 are the same or different and comprise at least one group selected from the group consisting of C1 - C6 alkyls, optionally the C1 - C6 alkyl may comprise one or more of oxygen, nitrogen, or sulfur atoms or a group comprising at least one of these atoms, and the alkyl chain may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate; R3 is selected from the group consisting of alkenyl, alkynyl, ester, alcohol, aryl alkyl, alkoxyalkyl ether, alkyl phosphate, C3 - C8 carboxylic acid, C1 - C10 alkyl benzoic acid, and a C1 - C6 linker attached to a second molecule of formula I, wherein the second molecule is the same or different; n is an integer from 1 to 12; X is selected from the group consisting of chloride, bromide, and iodide; At least one active ingredient; and Water component.
A preparation according to paragraph 5, comprising a buffer, and optionally one or more of a sweetener, flavoring agent, coloring agent and/or preservative.
A preparation comprising an additional thickener in accordance with paragraph 5 or 6.
In paragraph 7, a preparation that is one of drops, paste, salve, lotion, or ointment.
Healthcare emulsion including the following: At least one surfactant of chemical formula I: Herein, R1 and R2 are the same or different and comprise at least one group selected from the group consisting of C1 - C6 alkyls, optionally the C1 - C6 alkyl may comprise one or more of oxygen, nitrogen, or sulfur atoms or a group comprising at least one of these atoms, and the alkyl chain may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate; R3 is selected from the group consisting of alkenyl, alkynyl, ester, alcohol, aryl alkyl, alkoxyalkyl ether, alkyl phosphate, C3 - C8 carboxylic acid, C1 - C10 alkyl benzoic acid, and a C1 - C6 linker attached to a second molecule of formula I, wherein the second molecule is the same or different; n is an integer from 1 to 12; X is selected from the group consisting of chloride, bromide, and iodide; At least one active ingredient; aqueous phase; and Non-aqueous phase.
An emulsion according to claim 9, comprising a buffer, and optionally one or more of a sweetener, flavoring agent, coloring agent and/or preservative.
A method for manufacturing a healthcare preparation according to any one of claims 1 to 10, comprising the following: Step for synthesizing the compound of chemical formula I: Herein, R1 and R2 are the same or different and comprise at least one group selected from the group consisting of C1 - C6 alkyls, optionally the C1 - C6 alkyl may comprise one or more of oxygen, nitrogen, or sulfur atoms or a group comprising at least one of these atoms, and the alkyl chain may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate; R3 is selected from the group consisting of alkenyl, alkynyl, ester, alcohol, aryl alkyl, alkoxyalkyl ether, alkyl phosphate, C3 - C8 carboxylic acid, C1 - C10 alkyl benzoic acid, and a C1 - C6 linker attached to the second molecule of Formula I, wherein the second molecule is the same or different; n is an integer from 1 to 12; X is selected from the group consisting of chlorides, bromides, and iodides, and the method comprises the following: A ring-opening step of opening a lactam ring to provide an amino acid having an N-terminus and a C-terminus, A first alkylation step that alkylates the N-terminus to provide a tertiary amine, A coupling step of reacting the C-terminus with 3-aminopropyltris(trimethylsiloxy)silane to provide a siloxane derivative, and A second alkylation step of alkylating the N-terminus to provide a quaternary amine of formula I; and A step of adding at least one active ingredient.
In paragraph 11, the method in which the lactam is caprolactam.
A method according to claim 11 or 12, wherein in the first alkylation step, the tertiary amine is 6-(dimethylamino)hexanoic acid.
A method according to any one of claims 11 to 13, wherein in the second alkylation step, the N-terminus is alkylated with an alkylating agent selected from the group consisting of benzyl bromide, ethyl bromoacetate, allyl iodide, propargyl bromide, 1-bromo-2-(2-methoxyethoxy)ethane, bromophosphonate, 3-iodopropanol, 3-bromopropanol, 2-iodoethanol, 2-bromoethanol, 6-bromohexanoic acid, and 1,3-dibromopropane.
The use of any one of paragraphs 1 through 10 of the preparation as a healthcare preparation.

Description

Surfactants for use in healthcare products Cross-reference regarding related applications The present application claims priority to U.S. Provisional Application No. 63/531,206 filed on August 7, 2023, and to U.S. Application No. 18/795,165 filed on August 5, 2024, the entire disclosure thereof is incorporated by reference. field The present disclosure relates to surfactants for use in healthcare products. Such surfactants may include siloxane derivatives of amino acids having surface-active properties and methods for synthesizing the same. Surfactants (molecules with surface-active properties) are widely used in commercial applications in formulations ranging from detergents to hair care products and cosmetics. Compounds with surface-active properties are often added to formulations intended to improve human or animal health. Some healthcare products include pharmaceuticals, functional foods, vitamin and/or mineral supplements, and wound dressings. Surfactants are important ingredients in healthcare-designated or related formulations because, at least in part, they help increase the volume of active ingredients, stabilizers, fillers, excipients, adjuvants, etc., which can be included in convenient volume sizes, and/or because the inclusion of surfactants in formulations is useful for the manufacture and/or packaging of products. Surfactants can be uncharged, zwitterionic, cationic, or anionic. In principle, any class of surfactants (e.g., cationic, anionic, nonionic, amphoteric) is suitable for cleaning or cleaning applications, but in practice, many personal care cleansers and household cleaning products are formulated with a combination of two or more surfactants from two or more classes of surfactants. Often, surfactants are amphiphilic molecules possessing a relatively water-insoluble hydrophobic "tail" group and a relatively water-soluble hydrophilic "head" group. These compounds can be adsorbed at interfaces, such as between two liquids, between a liquid and a gas, or between a liquid and a solid. In systems containing a relatively polar component and a relatively non-polar component, the hydrophobic tail preferentially interacts with the relatively non-polar component(s), while the hydrophilic head preferentially interacts with the relatively polar component(s). In the case of an interface between water and oil, the hydrophilic head group preferentially faces water, while the hydrophobic tail preferentially faces oil. When added to a water-gas interface, the hydrophilic head group preferentially faces water, while the hydrophobic tail preferentially faces gas. The presence of a surfactant disrupts at least some of the intermolecular interactions between water molecules, thereby replacing at least some of the interactions between water molecules with the generally weaker interactions between at least some of the water molecules and the surfactant. This can lower surface tension and also stabilize the interface. At sufficiently high concentrations, surfactants can form aggregates, which act to limit the exposure of the hydrophobic tails to polar solvents. One such aggregate is a micelle. In a typical micelle, molecules are arranged in a sphere, with the hydrophobic tails of the surfactant(s) preferentially located inside the sphere and the hydrophilic heads preferentially located outside the micelle, where the heads preferentially interact with the more polar solvent. The effect of a given compound on surface tension and the concentration at which it forms micelles can play a role in defining the characteristics of the surfactant. The present disclosure provides healthcare products formulated using surfactants, which include, but are not limited to, tablets, powders, liquids, salves, ointments, cleansers and/or wipes, and wound dressings for use on the body. These products may be formulated to include one or more surfactants from one or more classes of surfactants disclosed herein. The present disclosure provides a surfactant for use in healthcare products in the form of a siloxane derivative of an amino acid having surface-active properties. The amino acid may be a naturally occurring or synthetic amino acid, or may be obtained through the ring-opening reaction of a molecule, such as a lactam, such as caprolactam. The amino acid may be functionalized with different types of siloxane groups to form a compound having surface-active properties. Characteristically, such a compound may have the ability to reduce a low critical micelle concentration (CMC) and/or the surface tension of a liquid. The present disclosure provides a formulation for delivering an active agent to a patient, comprising the following: Surfactant molecules having one or more structures of Chemical Formula I or II Herein, R1 and R2 may be the same or different and comprise at least one group selected from the group consisting of C1 - C6 alkyls, optionally the C1 - C6 alkyl may comprise one or more of oxygen, nitrogen, or sulfur atoms